The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases
Dupilumab reduced asthma exacerbations and improved symptom control without severe adverse reactions in paediatric patients with moderate-to-severe asthma and comorbid type 2 inflammatory diseases. It also decreased biomarkers of type 2 inflammation and improved lung function parameters, including both large and small airways. Considering the racial diversity, a large real-world study in China is required to confirm the role of dupilumab in paediatric patients with moderate-to-severe asthma and comorbid type 2 inflammatory diseases.
Authors
- Tingting Shi (ORCID: https://orcid.org/0000-0002-5686-6706)
- Cuiping Liang (ORCID: https://orcid.org/0000-0002-8002-7136)
- Gen Lu (ORCID: https://orcid.org/0000-0003-3224-5865)
- Yaping Xie (ORCID: https://orcid.org/0000-0001-9768-3730)
- Genquan Yin (ORCID: https://orcid.org/0000-0001-6258-7888)
- Rongshan Chen
- S.Y. Wu (ORCID: https://orcid.org/0000-0003-1189-2932)
- Chunhui He
Institutions
- Guangzhou Women and Children Medical Center (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- BMC Pulmonary Medicine
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1186/s12890-024-03414-x
- Citations
- 3
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.98
Funders
- Guangzhou Medical University